New research highlights the value of epigenomic testing in the routine assessment of neurodevelopmental and congenital disorders.

TOP INSIGHT
Genome-wide testing of DNA methylation, a mechanism of the epigenome, has been shown to facilitate the diagnosis of previously unsolved cases of neurodevelopmental or congenital abnormalities.
While currently there are limited treatment options associated with many of these conditions, providing a specific diagnosis can help physicians better predict the course of the disease, allowing for better planning and support for the patient. This research highlights the value of epigenomic testing in the routine assessment of neurodevelopmental and congenital disorders.
From this research, LHSC will be the first site in the world to offer this type of genetic testing. "We are excited to make this testing accessible to local patients, and across the world. Our lab has partnered and licensed this technology to Greenwood Genetics Laboratories in the United States and Amsterdam University Medical Centre Laboratories in the European Union", says Dr. Sadikovic. 100 per cent of revenue will be funneled back to support local testing for patients and ongoing research.
The study, "Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions" is published in the American Journal of Human Genetics.
This is one example of how Lawson is contributing to making Ontario Healthier, Wealthier and Smarter.
MEDINDIA




Email




